Otsuka Pharmaceutical Development & Commercialization, Inc. $4578.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS17
PHASE 3 / 2-312
RECRUITING8
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO33%
Delay Index: of 9 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Otsuka Pharmaceutical Development & Commercialization, Inc. on the live radar map → 📅 $4578.T readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Sibeprenlimab 400 mg NCT05248646 |
P3 | Active, not recruiting | Immunoglobulin A Nephropathy | 530 | 2026-05-13 (-8 mo) |
| SEP-363856 NCT06894212 |
P3 | Active, not recruiting | Schizophrenia | 538 | 2026-10-20 (-18 mo) |
| EnVISage NCT06928142 |
P2 | Active, not recruiting | Sjogren Disease | 83 | 2027-03-13 |
| Centanafadine XR NCT07759154 |
P3 | Recruiting | Attention-deficit/Hyperactivity Disorder; Emotional Dysregulation | 80 | 2027-05-27 |
| JNT-517 NCT06628128 |
P3 | Recruiting | Phenylketonuria (PKU) | 240 | 2027-11-01 |
| JNT-517 NCT06971731 |
P3 | Recruiting | Phenylketonuria | 120 | 2028-03-01 (+16 mo) |
| Sibeprenlimab NCT07861113 |
P2 | Not yet recruiting | Primary Membranous Nephropathy; Minimal Change Disease | 20 | 2028-06-15 |
| QUANTUM-TB NCT07209761 |
P3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis; Multidrug-Resistant Pulmonary Tuberculosis | 532 | 2028-09-29 (+16 mo) |
| SEP-363856 NCT07767903 |
P3 | Recruiting | Generalized Anxiety Disorder | 384 | 2028-10-25 |
| SEP-363856 NCT07759128 |
P3 | Recruiting | Generalized Anxiety Disorder | 576 | 2028-12-06 |
| Sibeprenlimab NCT06740526 |
P2 | Active, not recruiting | IgA Nephropathy | 56 | 2028-12-28 (-4 mo) |
| Sibeprenlimab 400 mg s.c. Q4weeks NCT05248659 |
P2/3 | Enrolling by invitation | Immunoglobulin A Nephropathy | 600 | 2028-12-28 |
| Tolvaptan Suspension NCT04782258 |
P3 | Recruiting | Autosomal Recessive Polycystic Kidney (ARPKD) | 20 | 2028-12-28 (+45 mo) |
| VIS954 NCT07933445 |
P2 | Not yet recruiting | Inflammatory Skin Diseases | 108 | 2029-03-13 |
| SEP-363856 NCT07786454 |
P3 | Recruiting | Generalized Anxiety Disorder | 1120 | 2029-05-26 |
| VIS954 NCT07904806 |
P2 | Not yet recruiting | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | 75 | 2029-11-20 |
| Sibeprenlimab NCT07770815 |
P3 | Not yet recruiting | IgA Nephropathy | 24 | 2029-12-29 |